<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7320610</article-id>
    <article-id pub-id-type="pmid">32282885</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btaa242</article-id>
    <article-id pub-id-type="publisher-id">btaa242</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Papers</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title><italic toggle="yes">CScape-somatic</italic>: distinguishing driver and passenger point mutations in the cancer genome</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7886-0674</contrib-id>
        <name>
          <surname>Rogers</surname>
          <given-names>Mark F</given-names>
        </name>
        <xref rid="btaa242-cor1" ref-type="corresp"/>
        <xref rid="btaa242-aff1" ref-type="aff">1</xref>
        <!--mark.f.rogers.phd@gmail.com-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gaunt</surname>
          <given-names>Tom R</given-names>
        </name>
        <xref rid="btaa242-aff2" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6485-6014</contrib-id>
        <name>
          <surname>Campbell</surname>
          <given-names>Colin</given-names>
        </name>
        <xref rid="btaa242-cor1" ref-type="corresp"/>
        <xref rid="btaa242-aff1" ref-type="aff">1</xref>
        <!--C.Campbell@bristol.ac.uk-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Robinson</surname>
          <given-names>Peter</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <aff id="btaa242-aff1"><label>1</label><institution>Intelligent Systems Laboratory</institution>, University of Bristol, Bristol BS8 1UB, <country country="GB">UK</country></aff>
    <aff id="btaa242-aff2"><label>2</label><institution>MRC Integrative Epidemiology Unit (IEU)</institution>, University of Bristol, Bristol BS8 2BN, <country country="GB">UK</country></aff>
    <author-notes>
      <corresp id="btaa242-cor1">To whom correspondence should be addressed. <email>mark.f.rogers.phd@gmail.com</email> or <email>C.Campbell@bristol.ac.uk</email></corresp>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>15</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2020-04-13">
      <day>13</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <volume>36</volume>
    <issue>12</issue>
    <fpage>3637</fpage>
    <lpage>3644</lpage>
    <history>
      <date date-type="received">
        <day>20</day>
        <month>11</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>4</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>07</day>
        <month>4</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Next-generation sequencing technologies have accelerated the discovery of single nucleotide variants in the human genome, stimulating the development of predictors for classifying which of these variants are likely functional in disease, and which neutral. Recently, we proposed <italic toggle="yes">CScape</italic>, a method for discriminating between cancer driver mutations and presumed benign variants. For the neutral class, this method relied on benign germline variants found in the 1000 Genomes Project database. Discrimination could, therefore, be influenced by the distinction of germline versus somatic, rather than neutral versus disease driver. This motivates this article in which we consider predictive discrimination between recurrent and rare somatic single point mutations based solely on using cancer data, and the distinction between these two somatic classes and germline single point mutations.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>For somatic point mutations in coding and non-coding regions of the genome, we propose <italic toggle="yes">CScape-somatic</italic>, an integrative classifier for predictively discriminating between recurrent and rare variants in the human cancer genome. In this study, we use <italic toggle="yes">purely cancer genome data</italic> and investigate the distinction between minimal occurrence and significantly recurrent somatic single point mutations in the human cancer genome. We show that this type of predictive distinction can give novel insight, and may deliver more meaningful prediction in both coding and non-coding regions of the cancer genome. Tested on somatic mutations, <italic toggle="yes">CScape-somatic</italic> outperforms alternative methods, reaching 74% balanced accuracy in coding regions and 69% in non-coding regions, whereas even higher accuracy may be achieved using thresholds to isolate high-confidence predictions.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>Predictions and software are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://CScape-somatic.biocompute.org.uk/" ext-link-type="uri">http://CScape-somatic.biocompute.org.uk/</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Contact</title>
        <p><email>mark.f.rogers.phd@gmail.com</email> or <email>C.Campbell@bristol.ac.uk</email></p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <label>1</label>
    <title>Introduction</title>
    <p>Next-generation sequencing technologies have accelerated the discovery of single-nucleotide variants (SNVs) in the human genome, stimulating the development of predictors for classifying which of these variants are likely functional in disease, and which neutral. Predictors have been developed for variants in both coding and noncoding regions of the human genome. For example, in <xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic> (2015)</xref>, we developed such a predictor based on pathogenic disease-driver germline variants from the Human Gene Mutation Database (<italic toggle="yes">HGMD</italic>) (<xref rid="btaa242-B33" ref-type="bibr">Stenson <italic toggle="yes">et al.</italic>, 2014</xref>), and assumed neutral variants from the 1000 Genomes Project Consortium (1000G) (<xref rid="btaa242-B35" ref-type="bibr">The 1000 Genomes Project Consortium, 2012</xref>). Multiple types of data may be informative, so we used an integrative binary classifier which weighted component data types according to their relative informativeness (<xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>). A variety of similar predictors have been proposed (<xref rid="btaa242-B1" ref-type="bibr">Adzhubei <italic toggle="yes">et al.</italic>, 2010</xref>; <xref rid="btaa242-B12" ref-type="bibr">Kircher <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btaa242-B13" ref-type="bibr">Kumar <italic toggle="yes">et al.</italic>, 2009</xref>; <xref rid="btaa242-B15" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="btaa242-B23" ref-type="bibr">Quang <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="btaa242-B24" ref-type="bibr">Reva <italic toggle="yes">et al.</italic>, 2011</xref>). In <xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic> (2017a</xref>), we proposed <italic toggle="yes">CScape</italic>, a classifier for predicting the driver status of SNVs in the human cancer genome with a follow-on investigation of biological insights in <xref rid="btaa242-B4" ref-type="bibr">Darbyshire <italic toggle="yes">et al.</italic> (2019)</xref>. By a <italic toggle="yes">driver</italic>, we mean a disease enabler, therefore including the sub-instances of gain-of-function, loss-of-function or both simultaneously.</p>
    <p>As tumors evolve, they accrue thousands of somatic mutations that are commonly labeled according to their role in cancer development: <italic toggle="yes">driver mutations</italic> are subject to positive selection during a tumor’s evolutionary progress, as they confer a growth advantage and contribute to tumor growth. <italic toggle="yes">Passenger mutations</italic> accumulate as tumors evolve, and may confer no advantage or may even inhibit tumor fitness (<xref rid="btaa242-B22" ref-type="bibr">Pon and Marra, 2015</xref>; <xref rid="btaa242-B34" ref-type="bibr">Stratton <italic toggle="yes">et al.</italic>, 2009</xref>). Oncogenesis is believed to be caused by a small number of key driver mutations (<xref rid="btaa242-B4" ref-type="bibr">Darbyshire <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btaa242-B17" ref-type="bibr">Martincorena <italic toggle="yes">et al.</italic>, 2017</xref>) that trigger tumor growth and induce subsequent passenger mutations as tumors proliferate (<xref rid="btaa242-B3" ref-type="bibr">Bozic <italic toggle="yes">et al.</italic>, 2010</xref>; <xref rid="btaa242-B19" ref-type="bibr">McFarland <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btaa242-B22" ref-type="bibr">Pon and Marra, 2015</xref>). Many more passenger than driver mutations exist in cancer cells and distinguishing between the two classes remains a significant challenge (<xref rid="btaa242-B18" ref-type="bibr">Marx, 2014</xref>). Germline mutations have been identified as drivers in genes such as <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>, but it is estimated that up to 90% of cancer-related genes are influenced by somatic mutations: those that accrue during a patient’s lifespan (<xref rid="btaa242-B7" ref-type="bibr">Futreal <italic toggle="yes">et al.</italic>, 2004</xref>). Furthermore, the immune system could be expected to tolerate germline mutations but remove cells with particular types of somatic mutation, leading to differing distributions between germline and somatic variation. Hence, understanding particular characteristics that differentiate somatic and germline mutation will be crucial to our understanding of how the disease progresses.</p>
    <p>In this article, we focus on a machine learning approach to distinguishing between driver and passenger SNVs across the human cancer genome. The development of such classifiers will be important for interpreting cancer sequence databases currently being compiled, such as the Cancer Genome Atlas (<xref rid="btaa242-B37" ref-type="bibr">Weinstein <italic toggle="yes">et al.</italic>, 2013</xref>), the International Cancer Genome Consortium (ICGC) (<xref rid="btaa242-B39" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2011</xref>) and national programmes, such as the Genomics England (100 000 genomes) Project. Mirroring previous methods (<xref rid="btaa242-B27" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2015</xref>, <xref rid="btaa242-B28" ref-type="bibr">2017a</xref>; <xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>), we use an integrative classifier and select features from a wide variety of data sources. Using leave-one-chromosome-out cross-validation (LOCO-CV), the proposed method, which we call <italic toggle="yes">CScape-somatic</italic>, outperforms alternative models, achieving balanced test accuracies of 74% in coding regions and 69% in non-coding regions.</p>
    <p>We also associate a confidence measure to the predicted class assignments (cf. <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S1</xref>). To interpret this confidence measure, in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S4</xref>, we consider two thresholds, a default threshold and a high-confidence threshold. If we restrict prediction to highest confidence instances only (<italic toggle="yes">cautious classification</italic>) then balanced accuracy in LOCO-CV increases to 92% for coding regions and 87% for non-coding regions, though with this level of test accuracy is confined to 10% of coding and 9% of non-coding nucleotide positions across the genome, respectively.</p>
  </sec>
  <sec>
    <label>2</label>
    <title>Materials and methods</title>
    <sec>
      <label>2.1</label>
      <title>Recurrence thresholds</title>
      <p>We assembled two datasets based on variants found in the COSMIC database (version 84, February 2018) (<xref rid="btaa242-B5" ref-type="bibr">Forbes <italic toggle="yes">et al.</italic>, 2010</xref>). Among the COSMIC database annotations is the recurrence level, or the number of times a mutation has been observed in different cases. In the discussion below, <italic toggle="yes">highly recurrent</italic> variants have a recurrence of <inline-formula id="IE1"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mo>ρ</mml:mo></mml:mrow></mml:math></inline-formula>, where we select <italic toggle="yes">ρ</italic> = 8 in non-coding regions and <italic toggle="yes">ρ</italic> = 7 in coding regions. The dependence of predictive accuracy on unseen validation data, versus recurrence level <italic toggle="yes">r</italic>, is depicted in <xref rid="btaa242-F1" ref-type="fig">Figure 1</xref>. For somatic variants, the other category of interest will be <italic toggle="yes">rare somatic</italic> SNVs which occur once in the whole dataset (<italic toggle="yes">r</italic> = 1). These two categories of somatic alterations will contain variants with differing disease-driver statuses. It is reasonable to assume that some highly recurrent variants, specific to cancer samples and absent from healthy individuals, are actually neutral passengers. A recurrent somatic SNV could be closely co-located within a region where there is an active disease driver. Similarly, a rare somatic SNV (<italic toggle="yes">r</italic> = 1) could actually be a rare driver. However, it is plausible to assume that <italic toggle="yes">recurrently observed somatic</italic> SNVs, which are restricted to cancer samples, are enriched for driver mutations. Similarly, <italic toggle="yes">rare somatic</italic> SNVs could be expected to be enriched for neutral variants. Even if this statement were challenged, we point out that the consequence of this study is to show that membership of these two classes can be predicted with a non-trivial accuracy on unseen test data, and hence these two classes must have different enrichments and characteristics. Our interest in discriminating <italic toggle="yes">recurrent somatic</italic> SNVs from <italic toggle="yes">rare somatic</italic> SNVs is therefore that it provides an alternative insight beyond a discrimination between germline neutrals (from healthy individuals) and recurrent somatic variants from cancer patients, absent from healthy individuals (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>). This latter distinction could be influenced by a bias toward germline versus somatic discrimination, rather than the intended distinction of passenger versus disease driver.</p>
      <fig position="float" id="btaa242-F1">
        <label>Fig. 1.</label>
        <caption>
          <p>Balanced accuracy for models at different COSMIC recurrence levels shows that the coding models achieve a peak validation accuracy of 74.1% at a recurrence threshold of <italic toggle="yes">ρ</italic> = 7 (top), whereas the non-coding models achieve a peak accuracy of 69.5% at a recurrence threshold of <italic toggle="yes">ρ</italic> = 8 (bottom)</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f1" position="float"/>
      </fig>
      <p>A further possible bias may be introduced if our class of negative examples, say the rare variants, are located in different genomic regions from the positive examples, the highly recurrent variants. For example, the positives may appear predominantly near transcription start sites while negatives are distributed more broadly (<xref rid="btaa242-B12" ref-type="bibr">Kircher <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btaa242-B26" ref-type="bibr">Ritchie <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>). To ensure the locations of rare somatic mutations approximate those of recurrent somatic mutations, we select only those rare mutations found within a window <italic toggle="yes">w</italic> of a recurrent mutation. For coding examples, we use <italic toggle="yes">w </italic>=<italic toggle="yes"> </italic>10 000, and for non-coding examples, we use <italic toggle="yes">w </italic>=<italic toggle="yes"> </italic>1000 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Section S1</xref>). Hence our final training sets, outlined in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S1 and S2</xref>, consist of 27 575 coding examples and 10 908 non-coding examples.</p>
    </sec>
    <sec>
      <label>2.2</label>
      <title>Feature groups</title>
      <p>All of our data are based on the GRCh37/hg19 version of the human genome and detailed further in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>. Following our previous work (<xref rid="btaa242-B27" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2015</xref>, <xref rid="btaa242-B29" ref-type="bibr">2017a,b</xref>; <xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>), we annotated our datasets using more than 30 <italic toggle="yes">feature groups</italic> that could be predictive of pathogenicity. For discriminating between somatic variants, we found the following feature categories to be predictive:</p>
      <list list-type="bullet">
        <list-item>
          <p><italic toggle="yes">Genomic</italic>: genomic features include GC content, local mutation frequency (<xref rid="btaa242-B16" ref-type="bibr">Martincorena and Campbell, 2015</xref>), sequence spectra (<xref rid="btaa242-B14" ref-type="bibr">Leslie <italic toggle="yes">et al.</italic>, 2002</xref>), proximity to gene features, such as splice sites or transcription factor binding sites, predicted functional elements and measures of region uniqueness.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Evolutionary</italic>: evolutionary features include a comprehensive set of conservation-based measures provided by tools, such as PhastCons (<xref rid="btaa242-B32" ref-type="bibr">Siepel <italic toggle="yes">et al.</italic>, 2005</xref>), PhyloP (<xref rid="btaa242-B21" ref-type="bibr">Pollard <italic toggle="yes">et al.</italic>, 2010</xref>) and FATHMM (<xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>).</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Consequences</italic> (<italic toggle="yes">coding only</italic>): using the Variant Effect Predictor (<xref rid="btaa242-B20" ref-type="bibr">McLaren <italic toggle="yes">et al.</italic>, 2016</xref>), we use binary vectors to represent allele consequences and the affected amino acids within all transcripts associated with a mutation.</p>
        </list-item>
      </list>
      <p>The COSMIC database also provides a set of <italic toggle="yes">mutational signatures</italic> that are specific to oncogenic mutations. These are associated with various distinct forms of mutation, such as DNA replication errors, defective DNA repair, enzymatic DNA modification and exposure to mutagens (<xref rid="btaa242-B2" ref-type="bibr">Alexandrov <italic toggle="yes">et al.</italic>, 2013</xref>). However, this signature set is still evolving and may represent only a subset of potential oncogenic driver signals. Furthermore, metrics used to derive some of these signatures are based in part on drivers gleaned from the COSMIC database and potentially could bias our models. Hence, our final models use seven distinct feature groups: <italic toggle="yes">Conservation</italic>, <italic toggle="yes">GC content</italic>, <italic toggle="yes">Sequence uniqueness</italic>, <italic toggle="yes">Local mutation frequency</italic>, <italic toggle="yes">Proximity to gene features</italic>, <italic toggle="yes">Spectrum</italic> and <italic toggle="yes">Functional elements</italic>. More detailed descriptions of these feature groups, and the machine learning method used, appear in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref> and in <xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic> (2017a</xref>).</p>
    </sec>
    <sec>
      <label>2.3</label>
      <title><italic toggle="yes">CScape-somatic</italic> models</title>
      <p>We evaluated all models using LOCO-CV testing (<xref rid="btaa242-T1" ref-type="table">Table 1</xref>), omitting mitochondrial and allosomal (X and Y) chromosomes from testing as these have evolutionary characteristics distinct from autosomal chromosomes, and tend to yield fewer examples. For each fold, we leave out one test chromosome while the remaining 21 chromosomes are used to train the model, using the same model parameters for all folds. Except where noted, we trained models using randomly selected, balanced sets of 4000 positive and 4000 negative examples. This smaller subset of examples yields accuracy nearly as high as with complete training sets but takes less time to train, and allows us to estimate the variability of test results across multiple LOCO-CV runs. For testing, we used all available examples for the left-out chromosome, resulting in slightly unbalanced test sets for coding and non-coding (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). For the training datasets, we balanced examples by class, and report results for balanced training for all test set estimations.</p>
      <table-wrap position="float" id="btaa242-T1">
        <label>Table 1.</label>
        <caption>
          <p>Statistics for <italic toggle="yes">CSS-noncoding</italic> and <italic toggle="yes">CSS-coding</italic> applied to LOCO-CV test data provide estimates of how the models are likely to perform on new examples</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
            <col valign="top" align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Classifier</th>
              <th rowspan="1" colspan="1">Bal. Acc.</th>
              <th rowspan="1" colspan="1">Sens.</th>
              <th rowspan="1" colspan="1">Spec.</th>
              <th rowspan="1" colspan="1">MCC</th>
              <th rowspan="1" colspan="1">PPV</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CSS-noncoding</italic>
              </td>
              <td rowspan="1" colspan="1">0.69</td>
              <td rowspan="1" colspan="1">0.64</td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">0.38</td>
              <td rowspan="1" colspan="1">0.73</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cautious (<inline-formula id="IE16"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:mo>τ</mml:mo><mml:mo>=</mml:mo><mml:mn>0.84</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
              <td rowspan="1" colspan="1">0.84</td>
              <td rowspan="1" colspan="1">0.87</td>
              <td rowspan="1" colspan="1">0.81</td>
              <td rowspan="1" colspan="1">0.67</td>
              <td rowspan="1" colspan="1">0.91</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CSS-coding</italic>
              </td>
              <td rowspan="1" colspan="1">0.74</td>
              <td rowspan="1" colspan="1">0.72</td>
              <td rowspan="1" colspan="1">0.77</td>
              <td rowspan="1" colspan="1">0.48</td>
              <td rowspan="1" colspan="1">0.76</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cautious (<inline-formula id="IE17"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:mo>τ</mml:mo><mml:mo>=</mml:mo><mml:mn>0.91</mml:mn></mml:mrow></mml:math></inline-formula>)</td>
              <td rowspan="1" colspan="1">0.92</td>
              <td rowspan="1" colspan="1">0.96</td>
              <td rowspan="1" colspan="1">0.88</td>
              <td rowspan="1" colspan="1">0.85</td>
              <td rowspan="1" colspan="1">0.93</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tblfn1">
            <p><italic toggle="yes">Note</italic>: Shown are the performance statistics for each model: sensitivity (<bold>Sens.</bold>, the proportion of positive examples correctly classified), specificity (<bold>Spec.</bold>, the proportion of negative examples correctly classified), balanced accuracy (<bold>Bal. Acc.</bold>), the Matthews correlation coefficient (<bold>MCC</bold>) and the positive predictive value (<bold>PPV</bold>, the proportion of positive predictions that are true positives). <italic toggle="yes">τ</italic> is the cutoff on the confidence for cautious classification.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>We integrated data from the feature groups outlined above and used them to train two distinct sub-classifiers: one for coding regions (<italic toggle="yes">CSS-coding</italic>), and a second for non-coding regions (<italic toggle="yes">CSS-noncoding</italic>). The simplest kernel method for integrating different data sources is to combine features from all sources into a single kernel. In previous work (<xref rid="btaa242-B29" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a,b</xref>), we have found that this approach yields excellent performance that may surpass multiple kernel methods (<xref rid="btaa242-B29" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017b</xref>), as single kernel methods allow models to learn interactions between features from different sources. Given at least 30 possible data sources, the number of possible combinations of feature groups makes exhaustive testing impractical. Instead, we use a forward selection approach based on previous work in which we found that sequential learning could be an effective means to identify an optimal combination of feature groups (<xref rid="btaa242-B27" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2015</xref>). To identify the data sources to include in each model, we first rank all feature groups by balanced accuracy. Starting with the top-ranked feature group by validation accuracy, we iterate over the remaining feature groups, creating models by combining each of the remaining groups with the top-ranked group to form a single kernel. If any of these models yield higher balanced accuracy than the best model, it becomes the new best model. We continue this process until none of the subsequent models yields significantly higher balanced accuracy than the current best model in LOCO-CV (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>). We evaluate all combinations with and without data normalization, where we standardize features by subtracting the mean and dividing by the standard deviation. For these models, we observed no difference in performance between the raw feature values and standardized data. The final <italic toggle="yes">CSS-noncoding</italic> model includes five feature groups: <italic toggle="yes">Conservation</italic>, <italic toggle="yes">Local mutation frequency</italic>, <italic toggle="yes">Distance from gene features</italic> and two related to sequence: <italic toggle="yes">GC content</italic> and <italic toggle="yes">Sequence uniqueness</italic>. For <italic toggle="yes">CSS-coding</italic>, the best model uses all of the feature groups used in <italic toggle="yes">CSS-noncoding</italic> plus the <italic toggle="yes">Functional elements</italic> and <italic toggle="yes">Spectrum</italic> groups (<xref rid="sup1" ref-type="supplementary-material">Supplementary Section S2</xref>).</p>
    </sec>
  </sec>
  <sec>
    <label>3</label>
    <title>Results</title>
    <sec>
      <label>3.1</label>
      <title>Measurable differences between germline and somatic neutral variants</title>
      <p>The methodology we use will be similar to that used with <italic toggle="yes">CScape</italic> (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>). However, the key difference is that we wish to explore the potential for discriminating between two different classes of somatic variants: highly recurrent SNVs, which we label as <italic toggle="yes">positives</italic>, and rare SNVs which we label as <italic toggle="yes">negatives</italic>. The other distinction is between the neutral germline variants we used to train our <italic toggle="yes">CScape</italic> models and the <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1 somatic SNVs in cancer samples. To investigate this latter distinction, we evaluated 30 different feature groups to detect differences between these latter two classes of variants.</p>
    </sec>
    <sec>
      <label>3.2</label>
      <title>Non-coding data: germline versus somatic</title>
      <p>In non-coding regions, several feature groups yielded different distributions for <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1 somatic variants and germline neutral variants. These are depicted in <xref rid="btaa242-F2" ref-type="fig">Figure 2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>, and the distinction is highly significant by hypothesis testing. For example, PhyloP conservation scores for <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1 somatic variants tend to be higher (associated with more highly conserved regions) and fall within a narrower range than neutral germline variants (<xref rid="btaa242-F2" ref-type="fig">Fig. 2</xref>, top). Based on our mutation tolerance measure, <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1 somatic variants reside in regions where somatic variants typically cluster, while benign germline variants appear in these regions less often (<xref rid="btaa242-F2" ref-type="fig">Fig. 2</xref>, bottom). These patterns are consistent with other features in the same groups (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>), and hence supports our hypothesis that by developing models focused solely on somatic variants, we may begin to tease out differences between cancer drivers and putative passenger variants. However, one should be cautious about drawing inferences from these results. For example, germline neutral variants have higher percent GC content scores in coding regions, but lower scores in non-coding regions, so it is unclear whether GC content plays a significant role, or whether it merely correlates with other features.</p>
      <fig position="float" id="btaa242-F2">
        <label>Fig. 2.</label>
        <caption>
          <p>Scoring distributions for SNVs in the <bold>non-coding</bold> datasets show differences between <italic toggle="yes">germline</italic> (1000 Genomes) and <italic toggle="yes">rare somatic</italic> (COSMIC, <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1) examples. The features that discriminate most clearly between germline and somatic variants are those associated with conservation scores (top) and the somatic mutation frequency within a local region (bottom). Conservation scores do not yield the kind of discrimination we see typically when comparing pathogenic or oncogenic mutants with presumed benign variants, however PhyloP scores suggest that putative somatic passenger variants are more closely associated with highly conserved regions (lower scores indicate greater conservation) than benign germline variants (top). This same pattern holds for other conservation scores, but the distinction is less clear (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>). Somatic variants also appear to reside in regions with higher mutation tolerance, as measured by the number of somatic variants found within a region of 1000 positions (bottom). The individual probabilities that the two distributions in each subplot come from the same underlying distribution are upper bounded by <inline-formula id="IE2"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, and hence the differences are certainly statistically significant</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f2" position="float"/>
      </fig>
    </sec>
    <sec>
      <label>3.3</label>
      <title>Coding data: germline versus somatic</title>
      <p>Conservation estimates feature prominently in many methods designed to predict pathogenic or oncogenic variants in coding regions of the genome, including our own FATHMM-MKL (<xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>), FATHMM-XF (<xref rid="btaa242-B29" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017b</xref>) and <italic toggle="yes">CScape</italic> (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>). The selection of positive examples (pathogenic or oncogenic) is relatively clear, but selecting appropriate neutral examples may be challenging. Hence, we used conservation scores to assess characteristic differences between neutral germline and somatic variants. For our analysis, we use three different methods for scoring conserved positions in a genome: <italic toggle="yes">PhastCons</italic> (<xref rid="btaa242-B32" ref-type="bibr">Siepel <italic toggle="yes">et al.</italic>, 2005</xref>), <italic toggle="yes">PHYLOP</italic> (<xref rid="btaa242-B21" ref-type="bibr">Pollard <italic toggle="yes">et al.</italic>, 2010</xref>) and <italic toggle="yes">FATHMM</italic> (<xref rid="btaa242-B30" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2013</xref>). <italic toggle="yes">PhastCons</italic> produces scores that correspond to the probability that a particular position is in a conserved region: high scores correspond to high conservation probability. <italic toggle="yes">PHYLOP</italic> yields scores in a broader range, but positive scores generally correspond to conserved regions and negative scores, to variable regions. <italic toggle="yes">FATHMM</italic> scores also span a relatively broad range. In this case, negative scores correspond to conserved regions and positive scores reflect variable regions.</p>
      <p>In coding regions, conservation scores tend to yield good discrimination between pathogenic and benign germline variants (<xref rid="btaa242-B29" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017b</xref>; <xref rid="btaa242-B31" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2015</xref>), or between somatic driver and neutral germline variants (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>). Hence, it is not surprising that several conservation scoring methods also exhibit different distributions between rare somatic variants and neutral germline variants in coding regions (<xref rid="btaa242-F3" ref-type="fig">Fig. 3</xref>). Here, we show the results for two methods: <italic toggle="yes">PhastCons</italic> (<xref rid="btaa242-B32" ref-type="bibr">Siepel <italic toggle="yes">et al.</italic>, 2005</xref>) and <italic toggle="yes">PHYLOP</italic> (<xref rid="btaa242-B21" ref-type="bibr">Pollard <italic toggle="yes">et al.</italic>, 2010</xref>) [we find similar results for scores from <italic toggle="yes">FATHMM</italic> (<xref rid="btaa242-B30" ref-type="bibr">Shihab <italic toggle="yes">et al.</italic>, 2013</xref>), <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3</xref>]. For conservation scores, we found that putative somatic passenger variants tend to have score distributions associated with more highly conserved regions than neutral germline variants. Note that, we observed the same pattern in conservation scores for non-coding variants, where rare somatic variants were also associated with more highly conserved regions (<xref rid="btaa242-F2" ref-type="fig">Fig. 2</xref>). These results are consistent with the idea that germline variants under selective pressure occur less frequently in conserved regions that are intolerant to variation. By contrast, rare somatic variants are under little or no selective pressure once tumors proliferate, and hence may tend to arise in conserved regions with a greater frequency.</p>
      <fig position="float" id="btaa242-F3">
        <label>Fig. 3.</label>
        <caption>
          <p>Two methods for estimating conservation in <bold>coding</bold> regions show that there are differences in scoring distributions between <italic toggle="yes">germline</italic> (1000 Genomes) and <italic toggle="yes">rare somatic</italic> (COSMIC, <italic toggle="yes">r </italic>=<italic toggle="yes"> </italic>1) variants. With PhastCons scores (top) germline neutral variants tend to have low scores associated with more highly conserved regions, whereas somatic neutral variants tend to have higher scores. PHYLOP scores (bottom) exhibit a similar pattern where again, high scores are associated with conserved regions, whereas low scores are associated with more variable regions. While these differences are subtle, this suggests that developing a coding region classifier strictly based on somatic variants may yield better specificity for cancer drivers than the current <italic toggle="yes">CScape</italic> coding model. The individual probabilities that the two distributions in each subplot come from the same underlying distribution are upper bounded by <inline-formula id="IE3"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM5" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, and hence the differences are certainly statistically significant</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f3" position="float"/>
      </fig>
    </sec>
    <sec>
      <label>3.4</label>
      <title>Classifying recurrent and rare somatic variants</title>
      <p>3.5 X indicate non-coding</p>
    </sec>
    <sec>
      <title>3.5.1 Classifying somatic variants in non-coding regions</title>
      <p>Cancer specific predictors have been proposed for prediction in coding regions of the cancer genome (<xref rid="btaa242-B1" ref-type="bibr">Adzhubei <italic toggle="yes">et al.</italic>, 2010</xref>; <xref rid="btaa242-B13" ref-type="bibr">Kumar <italic toggle="yes">et al.</italic>, 2009</xref>; <xref rid="btaa242-B38" ref-type="bibr">Wong <italic toggle="yes">et al.</italic>, 2011</xref>). General purpose predictors have also been proposed for prediction across the entire genome (coding and non-coding regions) using catalogued disease drivers across a variety of disease traits [e.g. HGMD (<xref rid="btaa242-B33" ref-type="bibr">Stenson <italic toggle="yes">et al.</italic>, 2014</xref>)], and recently, we have seen the emergence of classifiers designed to discriminate between cancer drivers and presumed benign variants from germline databases (<xref rid="btaa242-B6" ref-type="bibr">Fu <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>). However, there is currently a lack of predictors specifically trained to discriminate between somatically acquired putative drivers and passengers, particularly for non-coding regions of the cancer genome.</p>
      <p>Here, we consider the distinction between rare somatic variants and highly recurrent somatic variants, with the working assumption that the former class is enriched for neutral passengers while being distinct from germline neutrals, and with the latter class enriched for drivers. In <xref rid="btaa242-F4" ref-type="fig">Figure 4</xref>, we present results demonstrating that <italic toggle="yes">CSS-noncoding</italic> outperforms rival prediction tools for this distinction, based on the use of COSMIC data, both in terms of accuracy (top) and area-under-ROC-curve (AUC) score (bottom). In comparison with general-purpose classifiers such as CADD (<xref rid="btaa242-B12" ref-type="bibr">Kircher <italic toggle="yes">et al.</italic>, 2014</xref>), and cancer-specific methods such as <italic toggle="yes">CScape</italic> (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>) and FunSeq2 (<xref rid="btaa242-B6" ref-type="bibr">Fu <italic toggle="yes">et al.</italic>, 2014</xref>), our <italic toggle="yes">CScape-somatic</italic> model yields dramatically higher accuracy and AUC performance. <italic toggle="yes">CScape-somatic</italic> test accuracy with LOCO-CV is 69.2% while its nearest competitor, FunSeq2 yields 52.7%. Similarly, <italic toggle="yes">CScape-somatic</italic> yields an AUC score of 0.73 substantially higher than its nearest competitor, FunSeq2, with 0.52.</p>
      <fig position="float" id="btaa242-F4">
        <label>Fig. 4.</label>
        <caption>
          <p>Comparison between <italic toggle="yes">CScape-somatic</italic> performance in LOCO-CV (<bold>non-coding</bold> regions, <bold>COSMIC</bold> data) with prediction results for <italic toggle="yes">CScape</italic>, <italic toggle="yes">CADD</italic> and <italic toggle="yes">FunSeq2</italic> on the same examples (CSS= <italic toggle="yes">CScape-somatic</italic> and CS= <italic toggle="yes">CScape</italic>). Top: <italic toggle="yes">CScape-somatic</italic> dramatically outperforms other methods on the COSMIC training data with accuracy over 69%. Of the other methods, only <italic toggle="yes">FunSeq2</italic> appears to yield prediction accuracy better than chance, at 52.7%. The remaining methods fare poorly, including the original <italic toggle="yes">CScape</italic>. Bottom: We see the same trend with ROC scores, as <italic toggle="yes">CScape-somatic</italic> yields satisfactory ranking performance of 0.75, whereas only <italic toggle="yes">FunSeq2</italic> yields rankings better than chance</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f4" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.5.2 ICGC test data</title>
      <p>ICGC data include patient identifiers, which enables us to find cancer variants that occur more than once. Hence, this dataset provides a good independent test for models that might discriminate between putative driver mutations (those found in multiple patients) and rare, prospectively neutral, mutations (those found just once). Within the ICGC data, we found 52 825 examples in non-coding regions after we applied our strict filtering criteria. This procedure yielded 37 802 variants associated with only one patient, and 15 023 examples associated with two or more patients. We selected positive examples using three different recurrence levels: <inline-formula id="IE4"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM6" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE5"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> (we found no examples associated with more than four patients). In each case, we restricted rare variants to be within 1000 nucleotide positions of highly recurrent putative driver, to mitigate potential bias related to genomic locations. This yielded 37 802 rare variants and 15 023 recurrent variants at <inline-formula id="IE6"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM8" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, 3781 rare variants and 1548 recurrent variants at <inline-formula id="IE7"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM9" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> and 1207 rare variants and 481 recurrent variants at <inline-formula id="IE8"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM10" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
      <p>Generally, we found that <italic toggle="yes">CADD</italic>, which was trained solely on germline or simulated variants, and models such as <italic toggle="yes">CScape</italic>, <italic toggle="yes">FunSeq2</italic>, <italic toggle="yes">DANN</italic>, <italic toggle="yes">FATHMM-MKL</italic> and <italic toggle="yes">FATHMM-XF</italic>, trained on combinations of germline and somatic variants, perform poorly on this test set. <italic toggle="yes">CScape-somatic</italic> yields substantially higher balanced accuracy and AUC scores than competing methods on these data. Interestingly, this model performs better as the recurrence level increases: from 60% at <inline-formula id="IE9"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM11" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> up to 64% at <inline-formula id="IE10"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM12" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula> (<xref rid="btaa242-F5" ref-type="fig">Fig. 5</xref>). This observation implies there is a substantive difference between low-recurrence and high-recurrence variants, supporting our previously stated assumption that high-recurrence variants are more likely to be driver mutations. The remaining models all perform worse in terms of AUC scores as the ICGC driver threshold <italic toggle="yes">r</italic> increases, the lone exception being the original <italic toggle="yes">CScape</italic> (<xref rid="btaa242-F5" ref-type="fig">Fig. 5</xref>, bottom).</p>
      <fig position="float" id="btaa242-F5">
        <label>Fig. 5.</label>
        <caption>
          <p>Performance of the best <italic toggle="yes">CScape-somatic</italic> model with the original <italic toggle="yes">CScape</italic>, <italic toggle="yes">CADD</italic> and <italic toggle="yes">FunSeq2</italic> on the ICGC test set for <bold>non-coding</bold> regions (CSS= <italic toggle="yes">CScape-somatic</italic> and CS= <italic toggle="yes">CScape</italic>). Top: <italic toggle="yes">CScape-somatic</italic> yields accuracy from 60.0 up to 64.2% on the ICGC test sets, substantially higher than competitors. The closest competitor changes at each ICGC recurrence level: <italic toggle="yes">FunSeq2</italic> for ICGC <inline-formula id="IE11"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM13" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, at 50.9%; <italic toggle="yes">CScape</italic> for ICGC <inline-formula id="IE12"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM14" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, at 50.5% and <italic toggle="yes">CADD</italic> for ICGC <inline-formula id="IE13"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM15" display="inline" overflow="scroll"><mml:mrow><mml:mi>r</mml:mi><mml:mo>≥</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, at 51.4%. Bottom: <italic toggle="yes">CScape-somatic</italic> yields AUC scores from 0.64 to 0.73. None of the competitors yield scores better than random chance (0.50), and with the exception of the original <italic toggle="yes">CScape</italic>, perform worse as the driver threshold <italic toggle="yes">r</italic> increases</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f5" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.5.3 Evaluation on TERT/SDHD/PLEKHS1 examples from non-coding regions</title>
      <p>Few oncogenic single-point mutations have been verified in non-coding regions. The most prominent to date are three mutations in the <italic toggle="yes">TERT</italic> promoter region (<xref rid="btaa242-B9" ref-type="bibr">Horn <italic toggle="yes">et al.</italic>, 2013</xref>; <xref rid="btaa242-B10" ref-type="bibr">Huang <italic toggle="yes">et al.</italic>, 2013</xref>; <xref rid="btaa242-B36" ref-type="bibr">Weinhold <italic toggle="yes">et al.</italic>, 2014</xref>). These have been characterized as disruptions to putative <italic toggle="yes">E26 transformation specific</italic> (ETS) family transcription factor binding sites, that include five additional mutations in <italic toggle="yes">SDHD</italic> and <italic toggle="yes">PLEKHS1</italic> (<xref rid="btaa242-B36" ref-type="bibr">Weinhold <italic toggle="yes">et al.</italic>, 2014</xref>). This test set is tiny, and thus inadequate to evaluate classifiers in any comprehensive fashion, but represents the few documented examples of driver mutations in non-coding regions. Hence, we expect a useable classifier to predict a majority of these examples correctly. For both <italic toggle="yes">CScape</italic> methods, we assign negative (-) labels to scores below 0.5 and positive (+) labels for the rest. For CADD scores, we associate negative and positive predictions with negative and positive scores, respectively. For FunSeq2, we label as negative scores below 0.56 and use positive labels for the rest.</p>
      <p>The <italic toggle="yes">CScape-somatic</italic> non-coding predictor yield positive predictions for all of these examples, while the original <italic toggle="yes">CScape</italic> predict all but one of the <italic toggle="yes">SDHD</italic> examples (<xref rid="btaa242-T2" ref-type="table">Table 2</xref>). <italic toggle="yes">FunSeq2</italic> and <italic toggle="yes">CADD</italic> perform worst in this test, missing both of the <italic toggle="yes">PLEKHS1</italic> examples. However, it is worth repeating that these validated examples represent but a small fraction of cancer drivers in non-coding regions. It is also worth noting that none of these examples appear in the <italic toggle="yes">CScape-somatic</italic> training set, whereas all three of the TERT mutations were part of the original <italic toggle="yes">CScape</italic> training set.</p>
      <table-wrap position="float" id="btaa242-T2">
        <label>Table 2.</label>
        <caption>
          <p>Tests on verified cancer drivers from non-coding regions show that <italic toggle="yes">CScape-somatic</italic> predicts all variants correctly, while the original <italic toggle="yes">CScape</italic> correctly predicts all but one SDHD variant</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
            <col valign="top" align="center" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Mutation</th>
              <th rowspan="1" colspan="1">CSS</th>
              <th rowspan="1" colspan="1">CS</th>
              <th rowspan="1" colspan="1">FS<xref rid="tblfn3" ref-type="table-fn"><sup>a</sup></xref></th>
              <th rowspan="1" colspan="1">CADD</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td colspan="5" rowspan="1">TERT</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 5:g1295228G&gt;A</td>
              <td rowspan="1" colspan="1">+ (0.56)</td>
              <td rowspan="1" colspan="1">+ (0.52)</td>
              <td rowspan="1" colspan="1">+ (1.33)</td>
              <td rowspan="1" colspan="1">+ (0.34)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 5:g1295229G&gt;A</td>
              <td rowspan="1" colspan="1">+ (0.51)</td>
              <td rowspan="1" colspan="1">+ (0.62)</td>
              <td rowspan="1" colspan="1">+ (1.69)</td>
              <td rowspan="1" colspan="1">+ (0.66)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 5:g1295250G&gt;A</td>
              <td rowspan="1" colspan="1">+ (0.51)</td>
              <td rowspan="1" colspan="1">+ (0.58)</td>
              <td rowspan="1" colspan="1">+ (0.56)</td>
              <td rowspan="1" colspan="1">+ (0.31)</td>
            </tr>
            <tr>
              <td colspan="5" rowspan="1">SDHD</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 11:g111957523C&gt;T</td>
              <td rowspan="1" colspan="1">+ (0.52)</td>
              <td rowspan="1" colspan="1">+ (0.81)</td>
              <td rowspan="1" colspan="1">+ (1.00)</td>
              <td rowspan="1" colspan="1">+ (1.64)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 11:g111957541C&gt;T</td>
              <td rowspan="1" colspan="1">+ (0.68)</td>
              <td rowspan="1" colspan="1">+ (0.67)</td>
              <td rowspan="1" colspan="1">+ (1.62)</td>
              <td rowspan="1" colspan="1">+ (0.82)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 11:g111957544C&gt;T</td>
              <td rowspan="1" colspan="1">+ (0.87)</td>
              <td rowspan="1" colspan="1">− (0.40)</td>
              <td rowspan="1" colspan="1">+ (1.00)</td>
              <td rowspan="1" colspan="1">+ (0.64)</td>
            </tr>
            <tr>
              <td colspan="5" rowspan="1">PLEKHS1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 10:g115511590G&gt;A</td>
              <td rowspan="1" colspan="1">+ (0.71)</td>
              <td rowspan="1" colspan="1">+ (0.65)</td>
              <td rowspan="1" colspan="1">− (0.17)</td>
              <td rowspan="1" colspan="1">− (-0.10)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> 10:g115511593C&gt;T</td>
              <td rowspan="1" colspan="1">+ (0.57)</td>
              <td rowspan="1" colspan="1">+ (0.71)</td>
              <td rowspan="1" colspan="1">− (0.17)</td>
              <td rowspan="1" colspan="1">− (-0.06)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tblfn2">
            <p><italic toggle="yes">Note</italic>: <italic toggle="yes">FunSeq2</italic> and <italic toggle="yes">CADD</italic> predict the <italic toggle="yes">TERT</italic> and <italic toggle="yes">SDHD</italic> examples correctly, but both misclassify the <italic toggle="yes">PLEKHS1</italic> examples. For each method, we present the predicted label (+ = driver, – = passenger) with the associated score in parentheses. (Classifiers: CSS = <italic toggle="yes">CScape-somatic</italic>, CS = <italic toggle="yes">CScape</italic>, FS = FunSeq2.)</p>
          </fn>
          <fn id="tblfn3">
            <label>a</label>
            <p>For FunSeq2, we use a threshold of 0.56 (<xref rid="btaa242-B28" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2017a</xref>).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec>
      <title>3.6 X indicates coding</title>
      <sec>
        <title>3.6.1 Classifying somatic variants in coding regions</title>
        <p>For classifying driver mutations, coding regions have received considerably more attention than non-coding regions. However, few models have been developed expressly to differentiate between somatically acquired cancer drivers and passenger mutations. Hence, we are interested in seeing whether a classifier trained on rare putative passengers and highly recurrent putative drivers in coding regions can discriminate between these two classes, better than existing models. Results on our COSMIC training data, shown in <xref rid="btaa242-F6" ref-type="fig">Figure 6</xref>, show that most methods struggle to make this distinction. Of the methods tested, only the original <italic toggle="yes">CScape</italic> yields prediction accuracy better than chance, at 56% with an AUC score of 0.62. By contrast, <italic toggle="yes">CScape-somatic</italic> achieves an average balanced accuracy of 74% in LOCO-CV, with an average AUC of 0.82.</p>
        <fig position="float" id="btaa242-F6">
          <label>Fig. 6.</label>
          <caption>
            <p>Comparison between <italic toggle="yes">CScape-somatic</italic> performance using LOCO-CV (<bold>coding</bold> regions, <bold>COSMIC</bold> data) with prediction results for <italic toggle="yes">CScape</italic>, <italic toggle="yes">CADD</italic> and <italic toggle="yes">TransFIC</italic> (<xref rid="btaa242-B8" ref-type="bibr">Gonzalez-Perez <italic toggle="yes">et al.</italic>, 2012</xref>) models on the same examples. Top: <italic toggle="yes">CScape-somatic</italic> balanced accuracy in LOCO-CV outperforms other methods on the COSMIC training data, with accuracy over 74%. Of the other methods, only <italic toggle="yes">CScape</italic> yields prediction accuracy better than chance, at 59.2%. The remaining methods fare less well, even the TransFIC methods that were optimized for somatic variants. Bottom: We see the same trend with ROC scores, as <italic toggle="yes">CScape-somatic</italic> yields satisfactory ranking performance of 0.82, whereas only the original <italic toggle="yes">CScape</italic> yields rankings better than chance, at 0.62. (CSS= <italic toggle="yes">CScape-somatic</italic>; CS= <italic toggle="yes">CScape</italic>; TF-MAS= <italic toggle="yes">TransFIC-MutationAssessor</italic>, TF-PPH2= <italic toggle="yes">Transfic-Polyphen2</italic> and TF-SIFT= <italic toggle="yes">TransFIC-SIFT</italic>)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f6" position="float"/>
        </fig>
        <fig position="float" id="btaa242-F7">
          <label>Fig. 7.</label>
          <caption>
            <p>Performance of the best <italic toggle="yes">CScape-somatic</italic> model with the original <italic toggle="yes">CScape</italic>, <italic toggle="yes">CADD</italic> and <italic toggle="yes">TransFIC</italic> models on the <bold>ICGC test set</bold> for <bold>coding</bold> regions. Top: <italic toggle="yes">CScape-somatic</italic> yields substantially higher accuracy, at over 63%, than the original <italic toggle="yes">CScape</italic> at 59%. The remaining methods fare less well, with accuracies ranging from 51 to 56%. Bottom: When consider ranking performance, <italic toggle="yes">CScape-somatic</italic> again outperforms the other methods with an AUC score of 0.69, followed by the original <italic toggle="yes">CScape</italic> at 0.61 and the remaining methods all below 0.60. (CSS= <italic toggle="yes">CScape-somatic</italic>; CS= <italic toggle="yes">CScape</italic>; TF-MAS= <italic toggle="yes">TransFIC-MutationAssessor</italic>, TF-PPH2= <italic toggle="yes">Transfic-Polyphen2</italic> and TF-SIFT= <italic toggle="yes">TransFIC-SIFT.</italic>)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242f7" position="float"/>
        </fig>
      </sec>
      <sec>
        <title>3.6.2 ICGC test data</title>
        <p>We see similar performance characteristics on our ICGC test set: the <italic toggle="yes">CScape-somatic</italic> coding classifier yields 64% accuracy and an AUC score of 0.69, whereas the best of the remaining methods, <italic toggle="yes">CScape</italic>, manages 59% accuracy and an AUC of 0.61 (<xref rid="btaa242-F7" ref-type="fig">Fig. 7</xref>). Taken with the performance on our COSMIC dataset, these results suggest that models trained to discriminate between presumed cancer drivers and generic neutral germline variants may be poor with distinguishing between true drivers and passengers.</p>
        <p>We note that the performance of the <italic toggle="yes">CScape-somatic</italic> coding classifier drops considerably between the COSMIC training set and the ICGC test set. By contrast, the original <italic toggle="yes">CScape</italic> performs slightly better on the ICGC test set at 59% accuracy compared with 56% accuracy on the COSMIC dataset. There are two possible reasons for this: either the ICGC test set does not represent cancer drivers and putative passengers as well as the COSMIC dataset, or the <italic toggle="yes">CScape-somatic</italic> coding model may over-fit the COSMIC dataset. After filtering out examples found in our training set, the ICGC test sets are relatively small, with just 1695 drivers and 2921 putative passenger mutations in the set. As a result, we did not have sufficient test data to stratify by recurrence levels with putative drivers defined by recurrence levels as low as two. When we test our coding model on unseen COSMIC data where drivers are identified using recurrence levels of just two or higher, performance indeed drops considerably, to a balanced accuracy of 62.3%, slightly lower than its performance on the ICGC test data using the same recurrence levels. Thus, while we cannot rule out some degree of over-fitting, these results suggest that relatively low recurrence levels in the ICGC data account for some of the observed performance difference.</p>
        <p>We have used the COSMIC dataset for model training and the ICGC dataset for test evaluation. Of course, it is also possible to train on ICGC data and test on COSMIC. Though this leads to a slightly lower test performance, we consider and evaluate this alternative in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S5</xref>.</p>
        <p>Aside from evaluations on test data, we can also test the model for biologically meaningful prediction. There are a number of well-characterized cancer driver mutations stemming from variants in coding regions. For example, the <inline-formula id="IE14"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM16" display="inline" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">His</mml:mi><mml:mn>1047</mml:mn><mml:mi>A</mml:mi><mml:mi>r</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:math></inline-formula> substitution derives from <inline-formula id="IE15"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IM17" display="inline" overflow="scroll"><mml:mrow><mml:mi>A</mml:mi><mml:mo>→</mml:mo><mml:mi>G</mml:mi></mml:mrow></mml:math></inline-formula> at location 3:178952085 (GRCh37/hg19) in the driver gene <italic toggle="yes">PIK3CA</italic> and has been implicated in various cancers (<xref rid="btaa242-B11" ref-type="bibr">Janku <italic toggle="yes">et al.</italic>, 2011</xref>). Using <italic toggle="yes">CScape-somatic</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://CScape-somatic.biocompute.org.uk/" ext-link-type="uri">http://CScape-somatic.biocompute.org.uk/</ext-link>) this is a high confidence predicted driver (at 0.927). In <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S6</xref>, we further tested <italic toggle="yes">Cscape-somatic</italic> on a range of other recurring single point driver mutations in coding regions, residing in well-known cancer genes, and characterized as SNV drivers as shown in the Extended Data <xref rid="btaa242-F1" ref-type="fig">Figure 1</xref> in the study by <xref rid="btaa242-B25" ref-type="bibr">Rheinbay <italic toggle="yes">et al.</italic> (2017)</xref>. Their study uses data from the Pan-Cancer Analysis of Whole Genomes Consortium and uses in excess of 2700 cancer genomes from more than 2500 patients. Subject to the proviso given in <xref rid="sup1" ref-type="supplementary-material">Supplementary Section S6</xref>, the presented classifier correctly predicts all of these well-characterized drivers from the driver-genes <italic toggle="yes">KRAS</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">NRAS</italic> and <italic toggle="yes">IDH1</italic>.</p>
      </sec>
    </sec>
  </sec>
  <sec>
    <label>4</label>
    <title>Discussion</title>
    <p>In this study, we have investigated the feasibility of developing models that can accurately predict the likely influence of different classes of somatic mutations on tumorigenesis. Our hypothesis was twofold. First, there are characteristic differences in many of the features distinguishing rare somatic variants, which are prospectively enriched for neutral passenger variants, and benign germline variants. The latter category is frequently used to train methods for SNV driver status annotation. Second, these features can play an important role in discriminating between rare somatic variants, putatively passengers and highly recurrent somatic variants, restricted to cancer patients, and which are likely to be enriched for drivers. We found evidence to support the first hypothesis within features that measure degree of conservation across the genome, mutation frequency or GC content in the region surrounding each variant. We also present the <italic toggle="yes">CScape-somatic</italic> model to distinguish these two classes of somatic variant in coding and non-coding regions of the genome. Both the coding and non-coding sub-classifiers, optimized separately within their respective domains, rely to some degree on the same features: conservation, mutation frequency and GC content.</p>
    <p>To our knowledge, the <italic toggle="yes">CScape-somatic</italic> model is the first to discriminate solely between somatic cancer variants. We compared our new model to our original <italic toggle="yes">CScape</italic> model which was trained to discriminate between somatic driver variants and benign germline variants, and found that while the original model provides weak discrimination between highly recurrent and rare somatic variants, the new model provides substantially higher test accuracy across the entire genome. We also compared this new model to CADD, FunSeq2 and the three TransFIC models: TransFIC-MutationAssessor, TransFIC-SIFT and TransFIC-Polyphen2. Of these latter models, only FunSeq2 has been optimized to predict oncogenic variants. The remaining five methods were all developed to discriminate pathogenic germline variants from benign germline variants. In nearly all cases, we found that models trained on germline variants as the neutral control, were unable to distinguish between highly recurrent putative oncogenic drivers and rare somatic variants, likely to be putative passenger variants. Only models trained on cancer variants, <italic toggle="yes">CScape</italic> and <italic toggle="yes">FunSeq2</italic>, provided weak discrimination on some test data for this type of distinction. </p>
    <p><italic toggle="yes">Financial Support</italic>: The Integrative Epidemiology Unit is supported by the Medical Research Council (MC_UU_00011/4) and the University of Bristol, and we also acknowledge funding from the Cancer Research UK Integrative Cancer Epidemiology Programme (C18281/A19169).</p>
    <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btaa242_Supplementary_Data</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="btaa242_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btaa242-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adzhubei</surname><given-names>I.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>A method and server for predicting damaging missense mutations</article-title>. <source>Nat. Methods</source>, <volume>7</volume>, <fpage>248</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alexandrov</surname><given-names>L.B.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Signatures of mutational processes in human cancer</article-title>. <source>Nature</source>, <volume>500</volume>, <fpage>415</fpage>–<lpage>421</lpage>.<pub-id pub-id-type="pmid">23945592</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bozic</surname><given-names>I.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>Accumulation of driver and passenger mutations during tumor progression</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>107</volume>, <fpage>18545</fpage>–<lpage>18550</lpage>.<pub-id pub-id-type="pmid">20876136</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Darbyshire</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>Estimating the frequency of single point driver mutations across common solid tumours</article-title>. <source>Sci. Rep</source>., <volume>9</volume>, <fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">30626917</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Forbes</surname><given-names>S.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer</article-title>. <source>Nucleic Acids Res</source>., <volume>38</volume>, <fpage>D652</fpage>–<lpage>D950</lpage>.<pub-id pub-id-type="pmid">19906727</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer</article-title>. <source>Genome Biol</source>., <volume>15</volume>, <fpage>480</fpage>.<pub-id pub-id-type="pmid">25273974</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Futreal</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2004</year>) 
<article-title>A census of human cancer genes</article-title>. <source>Nat. Rev. Cancer</source>, <volume>4</volume>, <fpage>177</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">14993899</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gonzalez-Perez</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) 
<article-title>Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation</article-title>. <source>Genome Med</source>., <volume>4</volume>, <fpage>89</fpage>.<pub-id pub-id-type="pmid">23181723</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horn</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>TERT promoter mutations in familial and sporadic melanoma</article-title>. <source>Science</source>, <volume>339</volume>, <fpage>959</fpage>–<lpage>961</lpage>.<pub-id pub-id-type="pmid">23348503</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Highly recurrent TERT promoter mutations in human melanoma</article-title>. <source>Science</source>, <volume>339</volume>, <fpage>957</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">23348506</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Janku</surname><given-names>F.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers</article-title>. <source>PLoS One</source>, <volume>6</volume>, <fpage>e22769</fpage>.<pub-id pub-id-type="pmid">21829508</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kircher</surname><given-names>L.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>. <source>Nat. Genet</source>., <volume>46</volume>, <fpage>310</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">24487276</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>P.</given-names></string-name></person-group><etal>et al</etal> (<year>2009</year>) 
<article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>. <source>Nat. Protoc</source>., <volume>4</volume>, <fpage>1073</fpage>–<lpage>1081</lpage>.<pub-id pub-id-type="pmid">19561590</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leslie</surname><given-names>C.S.</given-names></string-name></person-group><etal>et al</etal> (<year>2002</year>) 
<article-title>The spectrum kernel: a string kernel for SVM protein classification</article-title>. <source>Pac. Symp. Biocomput</source>., <volume>7</volume>, <fpage>564</fpage>–<lpage>575</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa242-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>X.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>The performance of deleteriousness prediction scores for rare non-protein-changing single nucleotide variants in human genes</article-title>. <source>J. Med. Genet</source>., <volume>54</volume>, <fpage>134</fpage>–<lpage>144</lpage>.<pub-id pub-id-type="pmid">27999115</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martincorena</surname><given-names>I.</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>P.J.</given-names></string-name></person-group> (<year>2015</year>) 
<article-title>Somatic mutation in cancer and normal cells</article-title>. <source>Science</source>, <volume>349</volume>, <fpage>1483</fpage>–<lpage>1489</lpage>.<pub-id pub-id-type="pmid">26404825</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martincorena</surname><given-names>I.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>Universal patterns of selection in cancer and somatic tissues</article-title>. <source>Cell</source>, <volume>171</volume>, <fpage>1029</fpage>–<lpage>1041</lpage>.<pub-id pub-id-type="pmid">29056346</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marx</surname><given-names>V.</given-names></string-name></person-group> (<year>2014</year>) 
<article-title>Cancer genomes: discerning drivers from passengers</article-title>. <source>Nat. Methods</source>. <volume>11</volume>, <fpage>375</fpage>–<lpage>379</lpage>.<pub-id pub-id-type="pmid">24681722</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McFarland</surname><given-names>C.D.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>Tug-of-war between driver and passenger mutations in cancer and other adaptive processes</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>111</volume>, <fpage>15138</fpage>–<lpage>15143</lpage>.<pub-id pub-id-type="pmid">25277973</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McLaren</surname><given-names>W.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) 
<article-title>The ensembl variant effect predictor</article-title>. <source>Genome Biol</source>., <volume>17</volume>, <fpage>122</fpage>.<pub-id pub-id-type="pmid">27268795</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pollard</surname><given-names>K.S.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) 
<article-title>Detection of non-neutral substitution rates on mammalian phylogenies</article-title>. <source>Genome Res</source>., <volume>20</volume>, <fpage>110</fpage>–<lpage>121</lpage>.<pub-id pub-id-type="pmid">19858363</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pon</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Marra</surname><given-names>M.A.</given-names></string-name></person-group> (<year>2015</year>) 
<article-title>Driver and passenger mutations in cancer</article-title>. <source>Annu. Rev. Pathol. Mech. Dis</source>., <volume>10</volume>, <fpage>25</fpage>–<lpage>50</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa242-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quang</surname><given-names>D.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>DANN: a deep learning approach for annotating the pathogenicity of genetic variants</article-title>. <source>Bioinformatics</source>, <volume>31</volume>, <fpage>761</fpage>–<lpage>763</lpage>.<pub-id pub-id-type="pmid">25338716</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reva</surname><given-names>B.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>Predicting the functional impact of protein mutations: application to cancer genomics</article-title>. <source>Nucleic Acids Res</source>., <volume>39</volume>, <fpage>e118</fpage>–<lpage>e118</lpage>.<pub-id pub-id-type="pmid">21727090</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B25">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Rheinbay</surname><given-names>E.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) Discovery and characterization of coding and non-coding driver mutations in more than 2,500 whole cancer genomes. <italic toggle="yes">bioRxiv working paper</italic>.</mixed-citation>
    </ref>
    <ref id="btaa242-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ritchie</surname><given-names>G.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>Functional annotation of noncoding sequence variants</article-title>. <source>Nat. Methods</source>, <volume>11</volume>, <fpage>294</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">24487584</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B27">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) Sequential data selection for predicting the pathogenic effects of sequence variation. In: <italic toggle="yes">2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</italic>, pp. <fpage>639</fpage>–<lpage>644</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa242-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>M.F.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>a) 
<article-title>CScape: a tool for predicting oncogenic single-point mutations in the cancer genome</article-title>. <source>Sci. Rep</source>., <volume>7</volume>, <fpage>11597</fpage>.<pub-id pub-id-type="pmid">28912487</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>M.F.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>b) 
<article-title>FATHMM-XF: accurate prediction of pathogenic point mutations via extended features</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>511</fpage>–<lpage>513</lpage>.</mixed-citation>
    </ref>
    <ref id="btaa242-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shihab</surname><given-names>H.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Predicting the functional, molecular and phenotypic consequences of amino acid substitutions using hidden Markov models</article-title>. <source>Hum. Mutat</source>., <volume>34</volume>, <fpage>57</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">23033316</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shihab</surname><given-names>H.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>An integrative approach to predicting the functional effects of non-coding and coding sequence variation</article-title>. <source>Bioinformatics</source>, <volume>31</volume>, <fpage>1536</fpage>–<lpage>1543</lpage>.<pub-id pub-id-type="pmid">25583119</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siepel</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2005</year>) 
<article-title>Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes</article-title>. <source>Genome Res</source>., <volume>15</volume>, <fpage>1034</fpage>–<lpage>1050</lpage>.<pub-id pub-id-type="pmid">16024819</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stenson</surname><given-names>P.D.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>The human gene mutation database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine</article-title>. <source>Hum. Genet</source>., <volume>133</volume>, <fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">24077912</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stratton</surname><given-names>M.R.</given-names></string-name></person-group><etal>et al</etal> (<year>2009</year>) 
<article-title>The cancer genome</article-title>. <source>Nature</source>, <volume>458</volume>, <fpage>719</fpage>–<lpage>724</lpage>.<pub-id pub-id-type="pmid">19360079</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B35">
      <mixed-citation publication-type="journal">The 1000 Genomes Project Consortium. (<year>2012</year>) 
<article-title>An integrated map of genetic variation from 1,092 human genomes</article-title>. <source>Nature</source>, <volume>491</volume>, <fpage>56</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">23128226</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinhold</surname><given-names>N.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>Genome-wide analysis of noncoding regulatory mutations in cancer</article-title>. <source>Nat. Genet</source>., <volume>46</volume>, <fpage>1160</fpage>–<lpage>1165</lpage>.<pub-id pub-id-type="pmid">25261935</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>The cancer genome Atlas Pan-cancer analysis project</article-title>. <source>Nat. Genet</source>., <volume>45</volume>, <fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname><given-names>W.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer</article-title>. <source>Bioinformatics</source>, <volume>27</volume>, <fpage>2147</fpage>–<lpage>2148</lpage>.<pub-id pub-id-type="pmid">21685053</pub-id></mixed-citation>
    </ref>
    <ref id="btaa242-B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) 
<article-title>International cancer genome consortium data portal – a one-stop shop for cancer genomics data</article-title>. <source>Database</source>, <volume>2011</volume>, <fpage>bar026</fpage>–<lpage>bar026</lpage>.<pub-id pub-id-type="pmid">21930502</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
